New pill TJ0113 hopes to lift depression in 8 weeks

NCT ID NCT07018245

Recruiting now Symptom relief Sponsor: Hangzhou PhecdaMed Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests an experimental drug called TJ0113 for people with depression. About 150 adults aged 18 to 65 will take either 200 mg or 400 mg of TJ0113 or a placebo daily for 8 weeks. Researchers will measure changes in depression symptoms using a standard rating scale to see if the drug is safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TJ0113 capsules
What this could lead to: If it works, this could point toward a new oral treatment for depression that reduces symptoms like low mood and hopelessness.
What could go wrong: This is an early phase 2 trial with only 150 people, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEPRESSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Depression depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DEPRESSION

Contacts and locations

Locations

The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310009, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.